Key Series A Rounds: Allink, Celosia, Constrafor, Roon, and Doron Therapeutics

Episode 5 explores a diverse array of Series A funding rounds, starting with Allink Biotherapeutics securing $42 million, providing insights into their biotherapeutic advancements. Celosia Therapeutics' Series A funding is highlighted for its focus on ALS gene therapy. The episode also features Constrafor's impressive $264 million Series A, driving innovation in the construction industry. Additionally, Roon's Series A funding is covered, emphasizing expansion in women's health information, alongside Doron Therapeutics' Series A earmarked for Phase 3 clinical studies in osteoarthritis.